WO2025083656 - NOVEL CRYSTALLINE FORM OF LENACAPAVIR SODIUM AND PROCESSES FOR ITS PREPARATION
National phase entry is expected:
Publication Number
WO/2025/083656
Publication Date
24.04.2025
International Application No.
PCT/IB2024/060318
International Filing Date
21.10.2024
Title **
[English]
NOVEL CRYSTALLINE FORM OF LENACAPAVIR SODIUM AND PROCESSES FOR ITS PREPARATION
[French]
NOUVELLE FORME CRISTALLINE DE LÉNACAPAVIR SODIQUE ET SES PROCÉDÉS DE PRÉPARATION
Applicants **
APITORIA PHARMA PRIVATE LIMITED
Inventors
PRATAP REDDY, Mandad
SIVA RAMA KRISHNA, Muppalla
NASIR, Ali
PRAVEEN KUMAR, Neela
Priority Data
202341071851
20.10.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1956 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 1970 | |
| South Korea | Filing, Examination, Granting | 1739 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,581
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides a novel crystalline form of Lenacapavir sodium and a process for its preparation. The crystalline form of Lenacapavir sodium of the present invention herein designated as Form LEA-1 of Lenacapavir sodium, which is characterized by its PXRD pattern, DSC thermogram & thermogravimetric analysis.[French]
La présente invention concerne une nouvelle forme cristalline de lénacapavir sodique et un procédé pour sa préparation. La forme cristalline de lénacapavir sodique de la présente invention désignée ici sous la forme LEA-1 de lénacapavir sodique, qui est caractérisée par son diagramme PXRD, un thermogramme DSC et une analyse thermogravimétrique.